Prostate cancer: Molecular aspects, consequences, and opportunities of the multifocal nature
RI Skotheim, M Bogaard, KT Carm, U Axcrona… - … et Biophysica Acta (BBA …, 2024 - Elsevier
Prostate cancer is unique compared to other major cancers due to the presence of multiple
primary malignant foci in the majority of patients at the time of diagnosis. Each malignant …
primary malignant foci in the majority of patients at the time of diagnosis. Each malignant …
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer
J Fernandez-Mateos, GD Cresswell, N Trahearn… - Nature Cancer, 2024 - nature.com
Cancer evolution lays the groundwork for predictive oncology. Testing evolutionary metrics
requires quantitative measurements in controlled clinical trials. We mapped genomic …
requires quantitative measurements in controlled clinical trials. We mapped genomic …
CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression
H Cai, B Zhang, J Ahrenfeldt, JV Joseph… - Nature …, 2024 - nature.com
Metastatic prostate cancer (PCa) poses a significant therapeutic challenge with high
mortality rates. Utilizing CRISPR-Cas9 in vivo, we target five potential tumor suppressor …
mortality rates. Utilizing CRISPR-Cas9 in vivo, we target five potential tumor suppressor …
scSemiProfiler: Advancing large-scale single-cell studies through semi-profiling with deep generative models and active learning
J Wang, GJ Fonseca, J Ding - Nature Communications, 2024 - nature.com
Single-cell sequencing is a crucial tool for dissecting the cellular intricacies of complex
diseases. Its prohibitive cost, however, hampers its application in expansive biomedical …
diseases. Its prohibitive cost, however, hampers its application in expansive biomedical …
Precision medicine for prostate cancer: An international perspective
AA Hamid, CJ Sweeney, C Hovens, N Corcoran… - … Oncology: Seminars and …, 2024 - Elsevier
Greater personalization of cancer medicine continues to shape therapy development and
patient selection accordingly. The treatment of prostate cancer has evolved considerably …
patient selection accordingly. The treatment of prostate cancer has evolved considerably …
The Virtual Child
We are building the world's first Virtual Child–a computer model of normal and cancerous
human development at the level of each individual cell. The Virtual Child will “develop …
human development at the level of each individual cell. The Virtual Child will “develop …
Exploring the tumor genomic landscape of aggressive prostate cancer by whole‐genome sequencing of tissue or liquid biopsies
S Weiss, P Lamy, M Rusan, M Nørgaard… - … Journal of Cancer, 2024 - Wiley Online Library
Abstract Treatment resistance remains a major issue in aggressive prostate cancer (PC),
and novel genomic biomarkers may guide better treatment selection. Circulating tumor DNA …
and novel genomic biomarkers may guide better treatment selection. Circulating tumor DNA …
Genomic evolution shapes prostate cancer disease type
The development of cancer is an evolutionary process involving the sequential acquisition of
genetic alterations that disrupt normal biological processes, enabling tumor cells to rapidly …
genetic alterations that disrupt normal biological processes, enabling tumor cells to rapidly …
Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole-genome sequencing with …
S Rao, C Verrill, L Cerundolo, NK Alham, Z Kaya… - Genome Medicine, 2024 - Springer
Background Extension of prostate cancer beyond the primary site by local invasion or nodal
metastasis is associated with poor prognosis. Despite significant research on tumour …
metastasis is associated with poor prognosis. Despite significant research on tumour …
[HTML][HTML] Pan-cancer analysis of heterogeneity of tumor mutational burden and genomic mutation under treatment pressure
RJ Huang, YS Huang, N An, JJ Hu, CY Wu, YX Chen… - ESMO open, 2024 - Elsevier
Background High tumor mutational burden (TMB) is one of the widely researched predictive
biomarkers of immune checkpoint inhibitors and has been shown to be closely related with …
biomarkers of immune checkpoint inhibitors and has been shown to be closely related with …